- Home
- CERO vs HSCS Comparison
CERO vs HSCS Comparison
Compare CERO & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- HSCS
- Stock Information
- Founded
- CERO 2017
- HSCS 2007
- Country
- CERO United States
- HSCS United States
- Employees
- CERO N/A
- HSCS N/A
- Industry
- CERO
- HSCS Medical Specialities
- Sector
- CERO
- HSCS Health Care
- Exchange
- CERO Nasdaq
- HSCS Nasdaq
- Market Cap
- CERO 3.5M
- HSCS 3.7M
- IPO Year
- CERO N/A
- HSCS 2022
- Fundamental
- Price
- CERO $9.93
- HSCS $3.87
- Analyst Decision
- CERO Strong Buy
- HSCS Strong Buy
- Analyst Count
- CERO 2
- HSCS 2
- Target Price
- CERO $45.00
- HSCS $13.00
- AVG Volume (30 Days)
- CERO 3.3M
- HSCS 68.9K
- Earning Date
- CERO 08-13-2025
- HSCS 07-28-2025
- Dividend Yield
- CERO N/A
- HSCS N/A
- EPS Growth
- CERO N/A
- HSCS N/A
- EPS
- CERO N/A
- HSCS N/A
- Revenue
- CERO N/A
- HSCS N/A
- Revenue This Year
- CERO N/A
- HSCS N/A
- Revenue Next Year
- CERO N/A
- HSCS N/A
- P/E Ratio
- CERO N/A
- HSCS N/A
- Revenue Growth
- CERO N/A
- HSCS 261.17
- 52 Week Low
- CERO $6.71
- HSCS $2.36
- 52 Week High
- CERO $895.40
- HSCS $5.77
- Technical
- Relative Strength Index (RSI)
- CERO 50.09
- HSCS 52.06
- Support Level
- CERO $8.12
- HSCS $3.66
- Resistance Level
- CERO $13.14
- HSCS $4.03
- Average True Range (ATR)
- CERO 2.83
- HSCS 0.30
- MACD
- CERO 0.39
- HSCS 0.01
- Stochastic Oscillator
- CERO 19.58
- HSCS 41.11
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.